Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

PZ0385

Sigma-Aldrich

PFE-360

≥98% (HPLC)

Synonym(s):

1-Methyl-4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1H-pyrrole-2-carbonitrile, PF-06685360, PFE360

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H16N6O
CAS Number:
1527475-61-1
Molecular Weight:
308.34
UNSPSC Code:
12352202

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

room temp

SMILES string

CN1C(C#N)=CC(C2=CNC3=C2C(N4CCOCC4)=NC=N3)=C1

InChI key

IYQTYHISVSPMSU-UHFFFAOYSA-N

Biochem/physiol Actions

LRRK2 modulator
PFE-360 (PF-06685360) is a poten and elective inhibitor of LRRK2 kinase.

Legal Information

Sold for research purposes under agreement from Pfizer Inc.

pictograms

Flame
GHS02

signalword

Danger

hcodes

H242

Hazard Classifications

Self-react. C

Storage Class

5.2 - Organic peroxides and self-reacting hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000036114

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrew B West
Experimental neurology, 298(Pt B), 236-245 (2017-08-03)
In the translation of discoveries from the laboratory to the clinic, the track record in developing disease-modifying therapies in neurodegenerative disease is poor. A carefully designed development pipeline built from discoveries in both pre-clinical models and patient populations is necessary
Kenneth Thirstrup et al.
Scientific reports, 7(1), 10300-10300 (2017-09-02)
Genetic variation in the leucine-rich repeat kinase 2 (LRRK2) gene is associated with risk of familial and sporadic Parkinson's disease (PD). To support clinical development of LRRK2 inhibitors as disease-modifying treatment in PD biomarkers for kinase activity, target engagement and
Michael Aagaard Andersen et al.
Toxicology, 395, 15-22 (2018-01-09)
Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no existing therapeutic approach to delay or stop progression. Genetic, biochemical and pre-clinical studies have provided evidence that leucine-rich-repeat-kinase-2 (LRRK2) kinase is involved in the pathogenesis of PD

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service